Olesoxime (previously known as TRO19622)

A board to discuss future MS therapies in early stage (Phase I or II) trials.

Olesoxime (previously known as TRO19622)

Postby milica » Fri Mar 15, 2013 6:27 pm

I am not sure if this has been posted before
A Phase 1b study in RRMS patients is starting in three MS reference centers in France

About Olesoxime
Olesoxime (previously known as TRO19622) is a mitochondrial targeted, cholesterol-like compound that is currently undergoing Phase II clinical evaluation for the treatment of spinal muscular atrophy. Olesoxime's safety and tolerability has already been tested in 15 clinical trials involving 968 patients or healthy volunteers and has proved to have an excellent safety profile.
The mechanism of action of olesoxime involves prevention of mitochondrial dysfunction and improved microtubule dynamics, both implicated in neuroprotection and oligodendrocyte maturation. The ANR-funded MS-Repair project (ANR-08-BIOT-016-01) showed that the molecule is not only neuroprotective, but it also promotes myelination by accelerating the maturation of oligodendrocyte progenitor cells (OPCs) into mature oligodendrocytes. These studies were reported by Trophos and consortium partners from Aix-Marseille University and CNRS, IBDML (UMR 6216) and CRMBM (UMR 6612) in Annals of Neurology (Magalon et al, Ann Neurol. 2012;71:213-26).

User avatar
Getting to Know You...
Posts: 19
Joined: Sat Oct 28, 2006 3:00 pm


Return to Drug Pipeline


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service